Liquidia Corporation's shares rose 25% to $33.47 following a settlement of six pending lawsuits with United Therapeutics, ending years of patent and antitrust disputes. The settlement removes legal uncertainty around Liquidia's inhaled treprostinil treatment, YUTREPIA, for pulmonary arterial hypertension. Liquidia will pay $380.7 million in installments through April 2027, funded by cash reserves and YUTREPIA sales, without needing to raise additional funds. The agreement narrows YUTREPIA's approved label but allows Liquidia to focus on commercial expansion and meeting settlement obligations, marking a major shift in its competition with United Therapeutics' Tyvaso treatment.
Liquidia shares have surged significantly, trading at $34.07 on Pluang as of Oct 15, 2026 00:32 WIB, marking a 27.08% increase in one day. The stock's market capitalization stands at $2.40 billion, reflecting strong investor interest following the settlement news. Trading volume remains active with 2,857,547 shares exchanged, highlighting robust market activity around Liquidia.
